Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen - PubMed (original) (raw)
Clinical Trial
. 2005 Jan 15;105(2):879-85.
doi: 10.1182/blood-2004-03-0960. Epub 2004 Sep 14.
Affiliations
- PMID: 15367433
- DOI: 10.1182/blood-2004-03-0960
Free article
Clinical Trial
Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen
Kanchan Rao et al. Blood. 2005.
Free article
Abstract
The optimal approach to stem cell transplantation in children with immunodeficiency who lack a matched family donor is controversial. Unrelated donor stem cell transplantation gives equivalent outcome to mismatched family donor stem cell transplantation in severe combined immunodeficiency, whereas unrelated donors may be preferable in non-severe combined immunodeficiency children. However, unrelated donor stem cell transplantation with conventional conditioning regimens has been associated with significant treatment-related toxicity, particularly in non-severe combined immunodeficiency patients with preexisting organ dysfunction. We report the outcome of a series of 33 consecutive unrelated donor transplantations performed at our center in children with primary immunodeficiency using a reduced-intensity conditioning regimen between 1998 and 2001. We have compared these outcomes with a retrospective control cohort of 19 patients who underwent transplantation with myeloablative conditioning between 1994 and 1998. All children in both groups had primary engraftment. There was no statistical difference in the speed of immune reconstitution or incidence of graft-versus-host disease between the 2 groups. Overall survival was significantly better in the reduced-intensity conditioning group: 31 (94%) of 33 patients survived, compared with 10 (53%) of 19 in the myeloablative conditioning group (P = .014). We conclude that the reduced-intensity conditioning regimen results in improved survival and reduced transplantation-related mortality compared with myeloablative conditioning in high-risk patients undergoing unrelated donor transplantation.
Similar articles
- Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning.
Veys P, Rao K, Amrolia P. Veys P, et al. Bone Marrow Transplant. 2005 Mar;35 Suppl 1:S45-7. doi: 10.1038/sj.bmt.1704846. Bone Marrow Transplant. 2005. PMID: 15812530 - Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Bolaños-Meade J, Panepinto JA, Rondelli D, Shenoy S, Williamson J, Woolford TL, Gluckman E, Wagner JE, Tisdale JF. Eapen M, et al. Lancet Haematol. 2019 Nov;6(11):e585-e596. doi: 10.1016/S2352-3026(19)30154-1. Epub 2019 Sep 5. Lancet Haematol. 2019. PMID: 31495699 Free PMC article. - Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
Savani BN, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socié G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin NC, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A. Savani BN, et al. Haematologica. 2016 Jun;101(6):773-80. doi: 10.3324/haematol.2015.138180. Epub 2016 Mar 11. Haematologica. 2016. PMID: 26969081 Free PMC article. - Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S. Strober S. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review. - Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S, Aker M, Shapira MY, Resnick I, Bitan M, Or R. Slavin S, et al. Clin Transpl. 2003:275-82. Clin Transpl. 2003. PMID: 15387119 Review.
Cited by
- Personalized hematopoietic stem cell transplantation for inborn errors of immunity.
Slatter M, Lum SH. Slatter M, et al. Front Immunol. 2023 Apr 5;14:1162605. doi: 10.3389/fimmu.2023.1162605. eCollection 2023. Front Immunol. 2023. PMID: 37090739 Free PMC article. Review. - The Treatment of Primary Immune Deficiencies: Lessons Learned and Future Opportunities.
Paris K, Wall LA. Paris K, et al. Clin Rev Allergy Immunol. 2023 Aug;65(1):19-30. doi: 10.1007/s12016-022-08950-0. Epub 2022 Jul 1. Clin Rev Allergy Immunol. 2023. PMID: 35776401 Free PMC article. Review. - Clinical and Laboratory Factors Affecting the Prognosis of Severe Combined Immunodeficiency.
Ozturk E, Catak MC, Kiykim A, Baser D, Bilgic Eltan S, Yalcin K, Kasap N, Nain E, Bulutoglu A, Akgun G, Can Y, Sefer AP, Babayeva R, Caki-Kilic S, Tezcan Karasu G, Yesilipek A, Ozen A, Karakoc-Aydiner E, Baris S. Ozturk E, et al. J Clin Immunol. 2022 Jul;42(5):1036-1050. doi: 10.1007/s10875-022-01262-0. Epub 2022 Apr 22. J Clin Immunol. 2022. PMID: 35451701 - A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.
Vaezi M, Souri M, Setarehdan SA, Hamidieh AA, Fazlollahi MR, Pourpak Z, Badalzadeh M, Tajik S, Mahdaviani SA, Alimoghaddam K, Ghavamzadeh A. Vaezi M, et al. Ann Hematol. 2022 Apr;101(4):869-880. doi: 10.1007/s00277-022-04751-9. Epub 2022 Jan 8. Ann Hematol. 2022. PMID: 34997850 Review. - Endocrinopathies in Inborn Errors of Immunity.
Takasawa K, Kanegane H, Kashimada K, Morio T. Takasawa K, et al. Front Immunol. 2021 Nov 23;12:786241. doi: 10.3389/fimmu.2021.786241. eCollection 2021. Front Immunol. 2021. PMID: 34887872 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical